FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149908571> ?p ?o ?g. }

• W2149908571 endingPage "30" @default.
• W2149908571 startingPage "24" @default.
• W2149908571 abstract "<h2>Abstract</h2><h3>Background</h3> The combination of antiplatelet and anticoagulant therapy significantly reduces the rate of thromboembolic events in patients with heart valves compared with anticoagulant therapy alone. Cost-effectiveness of this therapy in Egypt, however, has not yet been established. <h3>Objective</h3> The aim of the present study was to evaluate the cost-effectiveness of the combined use of warfarin and low-dose aspirin (100 mg) versus warfarin alone in patients with mechanical aortic heart valve prostheses who began therapy at the age of 50 to 60 years over a 5-year period from the perspective of the medical providers. <h3>Methods</h3> A cohort Markov process model with five health states (recovery, reoperation, bleeding, thromboembolism, and death) based on Egyptian clinical practice was derived from published sources. The clinical parameters were derived from meta-analyses of randomized controlled trials of patients with mechanical valve prostheses. The quality of life of the health states was derived using the available published data. Direct medical costs were obtained from four top-rated governmental cardiology hospitals in Egypt. All costs and effects were discounted at 3.5% annually. All costs were converted using the purchasing power parity rate and are reported in US $ for the financial year of 2013. <h3>Results</h3> The total quality-adjusted life-years (QALYs) were estimated to be 1.1616 and 1.1199 for the warfarin plus aspirin group and the warfarin group, respectively, which resulted in a difference of 0.0416 QALYs. The total costs for the warfarin plus aspirin group and the warfarin group were US $307.33 and US $315.25, respectively (the difference was US $7.92), which yielded an incremental cost-effectiveness ratio of −190.38 for the warfarin plus aspirin group. Thus, the combined therapy was dominant. Various one-way sensitivity analyses indicated that probabilities of reoperation and bleeding in the recovery state had the greatest effects on incremental costs. The model parameters that had the greatest effects on incremental QALYs were the relative risk reduction of death and the utility value in the recovery state. <h3>Conclusions</h3> The present study is the first cost-utility analysis to conclude that, from the perspective of Egyptian medical providers, combined therapy is more effective and less costly than warfarin alone for patients with mechanical aortic valve prostheses. For clinicians and patients who choose to focus on minimizing thromboembolic risk, these results suggest that combined therapy offers the best protection. This study helps to inform decisions about the allocation of health care system resources and to achieve better health in the Egyptian population." @default.
• W2149908571 created "2016-06-24" @default.
• W2149908571 creator A5017626687 @default.
• W2149908571 creator A5024120973 @default.
• W2149908571 creator A5048712083 @default.
• W2149908571 creator A5058226396 @default.
• W2149908571 creator A5084669795 @default.
• W2149908571 creator A5084843366 @default.
• W2149908571 creator A5089498458 @default.
• W2149908571 date "2014-09-01" @default.
• W2149908571 modified "2023-10-03" @default.
• W2149908571 title "Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov Model" @default.
• W2149908571 cites W1986341674 @default.
• W2149908571 cites W2004337162 @default.
• W2149908571 cites W2022763183 @default.
• W2149908571 cites W2023449891 @default.
• W2149908571 cites W2032614363 @default.
• W2149908571 cites W2041617439 @default.
• W2149908571 cites W2063455447 @default.
• W2149908571 cites W2073358757 @default.
• W2149908571 cites W2074663212 @default.
• W2149908571 cites W2101836903 @default.
• W2149908571 cites W2108069441 @default.
• W2149908571 cites W2116656645 @default.
• W2149908571 cites W2118587875 @default.
• W2149908571 cites W2121224070 @default.
• W2149908571 cites W2127756743 @default.
• W2149908571 cites W2134926355 @default.
• W2149908571 cites W2135412352 @default.
• W2149908571 cites W2143025931 @default.
• W2149908571 cites W2143215274 @default.
• W2149908571 cites W2150712216 @default.
• W2149908571 cites W2157117527 @default.
• W2149908571 cites W2157718451 @default.
• W2149908571 cites W2163556807 @default.
• W2149908571 cites W2327876284 @default.
• W2149908571 cites W2328536190 @default.
• W2149908571 doi "https://doi.org/10.1016/j.vhri.2014.06.004" @default.
• W2149908571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29702802" @default.
• W2149908571 hasPublicationYear "2014" @default.
• W2149908571 type Work @default.
• W2149908571 sameAs 2149908571 @default.
• W2149908571 citedByCount "7" @default.
• W2149908571 countsByYear W21499085712016 @default.
• W2149908571 countsByYear W21499085712021 @default.
• W2149908571 countsByYear W21499085712022 @default.
• W2149908571 crossrefType "journal-article" @default.
• W2149908571 hasAuthorship W2149908571A5017626687 @default.
• W2149908571 hasAuthorship W2149908571A5024120973 @default.
• W2149908571 hasAuthorship W2149908571A5048712083 @default.
• W2149908571 hasAuthorship W2149908571A5058226396 @default.
• W2149908571 hasAuthorship W2149908571A5084669795 @default.
• W2149908571 hasAuthorship W2149908571A5084843366 @default.
• W2149908571 hasAuthorship W2149908571A5089498458 @default.
• W2149908571 hasBestOaLocation W21499085711 @default.
• W2149908571 hasConcept C112930515 @default.
• W2149908571 hasConcept C126322002 @default.
• W2149908571 hasConcept C141071460 @default.
• W2149908571 hasConcept C164705383 @default.
• W2149908571 hasConcept C168563851 @default.
• W2149908571 hasConcept C177713679 @default.
• W2149908571 hasConcept C2776301958 @default.
• W2149908571 hasConcept C2777628954 @default.
• W2149908571 hasConcept C2779161974 @default.
• W2149908571 hasConcept C3019080777 @default.
• W2149908571 hasConcept C64332521 @default.
• W2149908571 hasConcept C71924100 @default.
• W2149908571 hasConceptScore W2149908571C112930515 @default.
• W2149908571 hasConceptScore W2149908571C126322002 @default.
• W2149908571 hasConceptScore W2149908571C141071460 @default.
• W2149908571 hasConceptScore W2149908571C164705383 @default.
• W2149908571 hasConceptScore W2149908571C168563851 @default.
• W2149908571 hasConceptScore W2149908571C177713679 @default.
• W2149908571 hasConceptScore W2149908571C2776301958 @default.
• W2149908571 hasConceptScore W2149908571C2777628954 @default.
• W2149908571 hasConceptScore W2149908571C2779161974 @default.
• W2149908571 hasConceptScore W2149908571C3019080777 @default.
• W2149908571 hasConceptScore W2149908571C64332521 @default.
• W2149908571 hasConceptScore W2149908571C71924100 @default.
• W2149908571 hasLocation W21499085711 @default.
• W2149908571 hasLocation W21499085712 @default.
• W2149908571 hasOpenAccess W2149908571 @default.
• W2149908571 hasPrimaryLocation W21499085711 @default.
• W2149908571 hasRelatedWork W1991226583 @default.
• W2149908571 hasRelatedWork W2026273696 @default.
• W2149908571 hasRelatedWork W2028241366 @default.
• W2149908571 hasRelatedWork W2085270509 @default.
• W2149908571 hasRelatedWork W2137364748 @default.
• W2149908571 hasRelatedWork W2162649761 @default.
• W2149908571 hasRelatedWork W2165643497 @default.
• W2149908571 hasRelatedWork W2340043426 @default.
• W2149908571 hasRelatedWork W2367673278 @default.
• W2149908571 hasRelatedWork W243187273 @default.
• W2149908571 hasRelatedWork W2594351722 @default.
• W2149908571 hasRelatedWork W2599933528 @default.
• W2149908571 hasRelatedWork W2899972842 @default.
• W2149908571 hasRelatedWork W2906591861 @default.
• W2149908571 hasRelatedWork W2936532250 @default.

• next